Daniel Ricklin focuses on Complement system, Immunology, Complement, Inflammation and Innate immune system. His Complement system research integrates issues from Drug discovery and Cell biology. His research in Immunology intersects with topics in Neuroscience and Disease.
As a part of the same scientific family, Daniel Ricklin mostly works in the field of Complement, focusing on Transplant rejection and, on occasion, Clinical trial and Intensive care medicine. His Innate immune system research incorporates elements of Anaphylatoxin receptors, In vitro and Small molecule. His Complement component 2 research incorporates themes from Lectin pathway and CFHR5.
His primary areas of investigation include Complement system, Immunology, Complement, Biochemistry and Cell biology. Many of his studies on Complement system involve topics that are commonly interrelated, such as Innate immune system. Daniel Ricklin works mostly in the field of Immunology, limiting it down to concerns involving Neuroscience and, occasionally, Clinical trial.
The concepts of his Complement study are interwoven with issues in Computational biology, Disease, Drug discovery and Intensive care medicine. His Biochemistry study incorporates themes from Complement Inactivator Proteins, Complement factor B and Monoclonal antibody. His Cell biology research focuses on Receptor and how it relates to Anaphylatoxin receptors, Anaphylatoxin and Complement C5a.
The scientist’s investigation covers issues in Complement system, Immunology, Complement, Cell biology and Alternative complement pathway. His work on Eculizumab as part of general Complement system study is frequently connected to Regulator, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. Daniel Ricklin combines subjects such as Targeted therapy and Neuroscience with his study of Immunology.
Daniel Ricklin has researched Complement in several fields, including Bioinformatics, Drug discovery, Intensive care medicine, Disease and Drug. His Cell biology study integrates concerns from other disciplines, such as iC3b, Factor H, Complement component 2 and Binding site. The study incorporates disciplines such as Biochemistry and Classical complement pathway in addition to Alternative complement pathway.
His scientific interests lie mostly in Complement system, Immunology, Complement, Cell biology and Immune system. His study in the field of Eculizumab also crosses realms of Regulator. His research investigates the connection between Immunology and topics such as Neuroscience that intersect with problems in Disease pathogenesis.
His research on Complement also deals with topics like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: